CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge’s CAN108 New Drug Application, for Alagille Syndrome, Accepted by China’s National Medical Products Administration
Click here to view original post